Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Dec 27, 2023; 15(12): 2820-2830
Published online Dec 27, 2023. doi: 10.4240/wjgs.v15.i12.2820
Impact of hepatectomy and postoperative adjuvant transarterial chemoembolization on serum tumor markers and prognosis in intermediate-stage hepatocellular carcinoma
Yi-Di Hu, Hui Zhang, Wei Tan, Zhuo-Kai Li
Yi-Di Hu, Hui Zhang, Department of Surgery, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou 325000, Zhejiang Province, China
Wei Tan, Zhuo-Kai Li, Department of Hepatobiliary and Pancreatic Surgery, Lishui Municipal Central Hospital, Lishui 323000, Zhejiang Province, China
Author contributions: Hu YD conceptualized the study and played a pivotal role in the initial development of the research framework; Hu YD and Zhang H were instrumental in the statistical analysis and interpretation of the data, bringing critical insights into the study’s findings; Tan W contributed significantly by providing the necessary software support, and was responsible for the visualization and formatting of the images used in the study, enhancing the overall presentation and clarity of the research; Hu YD and Li ZK were a collaborative effort in the writing of the manuscript, with both authors contributing equally to the composition and refinement of the text; Li ZK also conducted a thorough review of all the research data, ensuring accuracy and integrity in the study’s results.
Institutional review board statement: The study was approved by the Medical Ethics Committee of Lishui Central Hospital. The ethical number is Research Ethics Approval (2023) No. (665).
Informed consent statement: The data used in this study were not involved in the patients’ privacy information, so the informed consent was waived by the Ethics Committee of Lishui Municipal Central Hospital. All patient data obtained, recorded, and managed only used for this study, and all patient information are strictly confidential, without any harm to the patients.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data covered within the article can be obtained from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhuo-Kai Li, MMed, Chief Doctor, Doctor, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, Lishui Municipal Central Hospital, No. 289 Kuocang Road, Lishui 323000, Zhejiang Province, China. lizhuokai@hotmail.com
Received: November 3, 2023
Peer-review started: November 3, 2023
First decision: November 16, 2023
Revised: November 22, 2023
Accepted: December 8, 2023
Article in press: December 8, 2023
Published online: December 27, 2023
Processing time: 54 Days and 2.4 Hours
Core Tip

Core Tip: This study investigated the efficacy of transhepatic arterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) after hepatectomy. When the post-treatment results of the observation group and the control group were compared, it was found that the inclusion of TACE significantly improved the clinical efficacy, reduced the levels of tumour markers and did not aggravate the damage to liver function. Thus, this may be an effective and comprehensive treatment strategy for patients with intermediate-stage HCC that helps to improve their quality of life and survival time.